Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Van Cutsem

Showing results (231-240 of 499) with videos related to

Pageof 50
Sort By:
The Oncologist|September 11, 2012
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensusRené Adam, Aimery De Gramont, Joan Figueras, et al.
Nature Medicine|September 23, 2024
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trialScott Kopetz, Danielle A Murphy, Jie Pu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancersMohamed E Salem, Alberto Puccini, Elizabeth Mauer, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 6, 2026
Multi-omic biomarkers of neoadjuvant treatment response in rectal cancer: A narrative reviewPieter Maerten, Albert Wolthuis, André D'Hoore, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOCElin Pauwels, Sofie Van Binnebeek, Vincent Vandecaveye, et al.
Clinical and Translational Radiation Oncology|August 22, 2022
Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort studyPhilippe P Bulens, Lien Smets, Annelies Debucquoy, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)Markus Moehler, Arno Schad, Annett Maderer, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 17, 2024
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyAndrew S Kennedy, Daniel B Brown, Marwan Fakih, et al.
Lancet (London, England)|November 29, 2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyMarianne E Pavel, John D Hainsworth, Eric Baudin, et al.
Pageof 50

Showing results (231-240 of 499) with videos related to

Sort By:
Pageof 50
The Oncologist|September 11, 2012
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensusRené Adam, Aimery De Gramont, Joan Figueras, et al.
Nature Medicine|September 23, 2024
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trialScott Kopetz, Danielle A Murphy, Jie Pu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT databaseQian Shi, Thierry Andre, Axel Grothey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancersMohamed E Salem, Alberto Puccini, Elizabeth Mauer, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 6, 2026
Multi-omic biomarkers of neoadjuvant treatment response in rectal cancer: A narrative reviewPieter Maerten, Albert Wolthuis, André D'Hoore, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 7, 2019
Inflammation-Based Index and <sup>68</sup>Ga-DOTATOC PET-Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with <sup>90</sup>Y-DOTATOCElin Pauwels, Sofie Van Binnebeek, Vincent Vandecaveye, et al.
Clinical and Translational Radiation Oncology|August 22, 2022
Nonoperative versus operative approach according to the response to neoadjuvant chemoradiotherapy for rectal cancer: A prospective cohort studyPhilippe P Bulens, Lien Smets, Annelies Debucquoy, et al.
Cancer Chemotherapy and Pharmacology|August 15, 2018
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)Markus Moehler, Arno Schad, Annett Maderer, et al.
Journal of Vascular and Interventional Radiology : JVIR|June 17, 2024
Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver MalignancyAndrew S Kennedy, Daniel B Brown, Marwan Fakih, et al.
Lancet (London, England)|November 29, 2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyMarianne E Pavel, John D Hainsworth, Eric Baudin, et al.
Pageof 50